Log in

STARPHARMA HOLD/S Stock Forecast, Price & News

+0.15 (+1.46 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $10.40
50-Day Range
MA: $11.30
52-Week Range
Now: $10.40
Volume586 shs
Average Volume1,554 shs
Market Capitalization$418.91 million
P/E RatioN/A
Dividend YieldN/A
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Commercial physical research



Sales & Book Value

Annual Sales$4.40 million
Book Value$0.56 per share



Market Cap$418.91 million
Next Earnings DateN/A
OptionableNot Optionable
+0.15 (+1.46 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPHRY News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHRY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

STARPHARMA HOLD/S (OTCMKTS:SPHRY) Frequently Asked Questions

How has STARPHARMA HOLD/S's stock price been impacted by Coronavirus?

STARPHARMA HOLD/S's stock was trading at $6.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPHRY shares have increased by 67.2% and is now trading at $10.40.
View which stocks have been most impacted by COVID-19

Are investors shorting STARPHARMA HOLD/S?

STARPHARMA HOLD/S saw a increase in short interest in September. As of September 30th, there was short interest totaling 4,300 shares, an increase of 168.8% from the September 15th total of 1,600 shares. Based on an average daily trading volume, of 3,700 shares, the days-to-cover ratio is presently 1.2 days.
View STARPHARMA HOLD/S's Short Interest

Who are some of STARPHARMA HOLD/S's key competitors?

Who are STARPHARMA HOLD/S's key executives?

STARPHARMA HOLD/S's management team includes the following people:
  • Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 56)
  • Mr. Nigel J. Baade, CFO & Company Sec.
  • Dr. A. Eglezos BSc(Hons), Ph.D., MBA, VP of Bus. Devel.
  • Dr. Jeremy R. Paull BSc (Hons), Ph.D., VP of Devel. & Regulatory Affairs
  • Dr. David J. Owen BSc(Hons) Ph.D., VP of Research

What is STARPHARMA HOLD/S's stock symbol?

STARPHARMA HOLD/S trades on the OTCMKTS under the ticker symbol "SPHRY."

How do I buy shares of STARPHARMA HOLD/S?

Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is STARPHARMA HOLD/S's stock price today?

One share of SPHRY stock can currently be purchased for approximately $10.40.

How big of a company is STARPHARMA HOLD/S?

STARPHARMA HOLD/S has a market capitalization of $418.91 million and generates $4.40 million in revenue each year.

What is STARPHARMA HOLD/S's official website?

The official website for STARPHARMA HOLD/S is www.starpharma.com.

How can I contact STARPHARMA HOLD/S?

STARPHARMA HOLD/S's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at 61-3-8532-2700 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.